A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
Price : $35 *
At a glance
- Drugs Paclitaxel trevatide (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors AngioChem
- 31 Aug 2018 Biomarkers information updated
- 20 Sep 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.